Evidence map›Paper›PMID 33867046›Full record

Trial reportPhytomedicine : international journal of phytotherapy and phytopharmacology2021

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.

Ke Hu, Wei-Jie Guan, Ying Bi, Wei Zhang, Lanjuan Li, Boli Zhang, Qingquan Liu, Yuanlin Song, Xingwang Li, Zhongping Duan and 9 more

Erratum issuedOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 269 papers, 25 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
269citing papers in PubMed, 25 pooled it
69.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

269 citing papers in PubMed, 25 syntheses or guidelines pooled it, 461 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021
    Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

209 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 1 country.

Ke HuDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Zhangzhidong Road No. 99, Wuhan 430060, Hubei province, China.
Wei-Jie GuanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong province, 510120 PR China.
Ying BiDepartment of Gynaecology and Obstetrics, Wuhan Red Cross Hospital, 392 Hongkong Road, Wuhan 430015, Hubei province, China.
Wei ZhangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Lanjuan LiThe First Affiliated Hospital of College of Medicine, Zhejiang province, China.
Boli ZhangThe First Teaching Hospital of Tianjin University of traditional Chinese medicine.
Qingquan LiuBeijing Hospital of traditional Chinese medicine, Beijing, China.
Yuanlin SongZhongshan Hospital Affiliated Fudan University, Shanghai, China.
Xingwang LiBeijing Ditan Hospital Capital Medical University, Beijing, China.
Zhongping DuanYouan Hospital Capital Medical University, Beijing, China.
Qingshan ZhengShanghai University of traditional Chinese medicine, Shanghai, China.
Zifeng YangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong province, 510120 PR China.
Jingyi LiangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong province, 510120 PR China.
Mingfeng HanFuyang Second People's Hospital, Fuyang, China.
Lianguo RuanWuhan Jinyintan Hospital, Wuhan, Hubei province, China.
Chaomin WuZhongshan Hospital Affiliated Fudan University, Shanghai, China.
Yunting ZhangDepartment of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Zhangzhidong Road No. 99, Wuhan 430060, Hubei province, China.
Zhen-Hua JiaHebei Yiling Hospital, National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, Hebei province 050035 PR China. Electronic address: jzhjiazhenhua@163.com.
Nan-Shan ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong province, 510120 PR China. Electronic address: nanshan@vip.163.com.
First Affiliated Hospital of Guangzhou Medical University · CNCapital Medical University · CNFudan University · CNWuhan University · CNBeijing Hospital of Traditional Chinese Medicine · CNFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine · CNFuyang Second People's Hospital · CNHangzhou Medical College · CNHebei Yiling Hospital · CNJinyintan Hospital · CNNanchang University · CNShanghai University of Traditional Chinese Medicine · CNWuhan Red Cross Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (Covid-19) has resulted in a global outbreak. Few existing targeted medications are available. Lianhuaqingwen (LH) capsule, a repurposed marketed Chinese herb product, has been proven effective for influenza. PURPOSE: To determine the safety and efficacy of LH capsule in patients with Covid-19.

methodsWe did a prospective multicenter open-label randomized controlled trial on LH capsule in confirmed cases with Covid-19. Patients were randomized to receive usual treatment alone or in combination with LH capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery.

resultsWe included 284 patients (142 each in treatment and control group) in the full-analysis set. The recovery rate was significantly higher in treatment group as compared with control group (91.5% vs. 82.4%, p = 0.022). The median time to symptom recovery was markedly shorter in treatment group (median: 7 vs. 10 days, p < 0.001). Time to recovery of fever (2 vs. 3 days), fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in treatment group (all p < 0.001). The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, p < 0.001) and clinical cure (78.9% vs. 66.2%, p = 0.017) was also higher in treatment group. However, both groups did not differ in the rate of conversion to severe cases or viral assay findings (both p > 0.05). No serious adverse events were reported.

conclusionIn light of the safety and effectiveness profiles, LH capsules could be considered to ameliorate clinical symptoms of Covid-19.

Indexed as

COVID-19 Drug TreatmentDrug RepositioningAdultAgedCapsulesChinaDrugs, Chinese HerbalFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeCapsulesDrugs, Chinese Herballianhuaqingwenconversion rateCoronavirus disease 2019Lianhuaqingwen CapsuleSymptom recovery

Identifiers

PMID33867046
PMCPMC7229744
OpenAlexW3024536180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.